Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, dose-escalation, phase I study to evaluate the safety,
tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of CAL056
mesylate in cancer patients with resistant or refractory solid tumors.